Document Type
Article
Publication Date
12-5-2024
Abstract
Contradictory results have been reported about the effects of liver diseases on the blood-brain barrier (BBB) permeability to markers. For instance, both an increase and no change in the BBB permeability to BBB markers sodium fluorescein and Evans blue have been reported in experimental cholestasis induced by bile duct ligation (BDL) in rats. These contradictory effects might be due to inherent limitations of these markers and/or methodological issues. Here, we investigated the time course of the impact of BDL in rats on BBB permeability using a recently developed stable isotope labeled marker [13C]sucrose, which is expected to be devoid of limitations of other markers, such as sodium fluorescein. At various times (five days, two weeks, and four weeks) after BDL or sham surgery, the brain uptake clearance (Kin) of [13C]sucrose was estimated using quantitation of the marker in plasma, blood, and brain by a specific LC-MS/MS analytical method. BDL caused substantial increases in the plasma concentrations of liver biochemical markers (bilirubin, total bile acids, ammonia, and cholesterol) and reduced liver cytochrome P450 content and metabolic activities. However, compared with the sham group, the plasma or blood AUC, brain concentrations, and Kin of [13C]sucrose in BDL animals remained unchanged at all the studied times. Additionally, we observed a negative correlation between the sucrose Kin and plasma total bile acids concentrations in the BDL animals. It is concluded that cholestatic liver disease, induced by BDL surgery in rats, does not significantly affect the BBB permeability to sucrose up to 4 weeks after the surgery.
Recommended Citation
Miah, M.K., Bickel, U. & Mehvar, R. Bile duct ligation-induced cirrhosis does not alter the blood-brain barrier permeability to sucrose in rats. Metab Brain Dis 40, 53 (2025). https://doi.org/10.1007/s11011-024-01486-6
Supplementary file1
Copyright
The authors
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Included in
Animal Experimentation and Research Commons, Digestive System Diseases Commons, Nervous System Diseases Commons, Other Pharmacy and Pharmaceutical Sciences Commons
Comments
This article was originally published in Metabolic Brain Disease, volume 40, in 2024. https://doi.org/10.1007/s11011-024-01486-6